Stephanie David - Search Results

Year	Number of Results
2004	1
2009	2
2010	4
2011	4
2012	5
2013	4
2014	2
2015	3
2016	2
2017	2
2018	4
2019	2
2020	2
2022	6
2023	3
2024	1

1

Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.

Eljack S, David S, Faggad A, Chourpa I, Allard-Vannier E. Eljack S, et al. Among authors: david s. Int J Pharm X. 2022 Sep 6;4:100126. doi: 10.1016/j.ijpx.2022.100126. eCollection 2022 Dec. Int J Pharm X. 2022. PMID: 36147518 Free PMC article.

2

Two-step formulation of magnetic nanoprobes for microRNA capture.

Vilímová I, Chourpa I, David S, Soucé M, Hervé-Aubert K. Vilímová I, et al. Among authors: david s. RSC Adv. 2022 Mar 2;12(12):7179-7188. doi: 10.1039/d1ra09016j. eCollection 2022 Mar 1. RSC Adv. 2022. PMID: 35424703 Free PMC article.

3

Nature as a source of inspiration for cationic lipid synthesis.

Labas R, Beilvert F, Barteau B, David S, Chèvre R, Pitard B. Labas R, et al. Among authors: david s. Genetica. 2010 Feb;138(2):153-68. doi: 10.1007/s10709-009-9405-8. Epub 2009 Sep 11. Genetica. 2010. PMID: 19763845 Review.

4

Non-viral nanosystems for systemic siRNA delivery.

David S, Pitard B, Benoît JP, Passirani C. David S, et al. Pharmacol Res. 2010 Aug;62(2):100-14. doi: 10.1016/j.phrs.2009.11.013. Epub 2009 Dec 17. Pharmacol Res. 2010. PMID: 20006707 Free article. Review.

5

Novel long-circulating lipid nanocapsules.

Hoarau D, Delmas P, David S, Roux E, Leroux JC. Hoarau D, et al. Among authors: david s. Pharm Res. 2004 Oct;21(10):1783-9. doi: 10.1023/b:pham.0000045229.87844.21. Pharm Res. 2004. PMID: 15553223

6

Smart PEG-Block-PLA/PLA Nanosystems: Impact of the Characteristics of the Polymer Blend on the Redox Responsiveness.

Van Gheluwe L, David S, Buchy E, Chourpa I, Munnier E. Van Gheluwe L, et al. Among authors: david s. Materials (Basel). 2023 Jan 5;16(2):539. doi: 10.3390/ma16020539. Materials (Basel). 2023. PMID: 36676276 Free PMC article.

7

Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment.

Eljack S, David S, Chourpa I, Faggad A, Allard-Vannier E. Eljack S, et al. Among authors: david s. Pharmaceuticals (Basel). 2022 Nov 23;15(12):1452. doi: 10.3390/ph15121452. Pharmaceuticals (Basel). 2022. PMID: 36558904 Free PMC article.

8

In vitro synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model.

Nguyen PV, Hervé-Aubert K, Lajoie L, Misericordia Y, Chourpa I, David S, Allard-Vannier E. Nguyen PV, et al. Among authors: david s. Int J Pharm X. 2022 Nov 13;4:100139. doi: 10.1016/j.ijpx.2022.100139. eCollection 2022 Dec. Int J Pharm X. 2022. PMID: 36420371 Free PMC article.

9

Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells.

Eljack S, Allard-Vannier E, Misericordia Y, Hervé-Aubert K, Aubrey N, Chourpa I, Faggad A, David S. Eljack S, et al. Among authors: david s. Pharmaceutics. 2022 Nov 21;14(11):2537. doi: 10.3390/pharmaceutics14112537. Pharmaceutics. 2022. PMID: 36432729 Free PMC article.

10

MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.

David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA. David SN, et al. Prostate. 2018 Jun;78(8):616-622. doi: 10.1002/pros.23506. Epub 2018 Mar 14. Prostate. 2018. PMID: 29542165

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

40 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year